Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
2.
Oncogene ; 35(14): 1785-96, 2016 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-26234676

RESUMEN

Accumulating evidence suggests that changes of the protein synthesis machinery alter translation of specific mRNAs and participate in malignant transformation. Here we show that protein kinase C α (PKCα) interacts with TRM61, the catalytic subunit of the TRM6/61 tRNA methyltransferase. The TRM6/61 complex is known to methylate the adenosine 58 of the initiator methionine tRNA (tRNAi(Met)), a nuclear post-transcriptional modification associated with the stabilization of this crucial component of the translation-initiation process. Depletion of TRM6/61 reduced proliferation and increased death of C6 glioma cells, effects that can be partially rescued by overexpression of tRNAi(Met). In contrast, elevated TRM6/61 expression regulated the translation of a subset of mRNAs encoding proteins involved in the tumorigenic process and increased the ability of C6 cells to form colonies in soft agar or spheres when grown in suspension. In TRM6/61/tRNAi(Met)-overexpressing cells, PKCα overexpression decreased tRNAi(Met) expression and both colony- and sphere-forming potentials. A concomitant increase in TRM6/TRM61 mRNA and tRNAi(Met) expression with decreased expression of PKCα mRNA was detected in highly aggressive glioblastoma multiforme as compared with Grade II/III glioblastomas, highlighting the clinical relevance of our findings. Altogether, we suggest that PKCα tightly controls TRM6/61 activity to prevent translation deregulation that would favor neoplastic development.


Asunto(s)
Biomarcadores de Tumor/biosíntesis , Glioblastoma/genética , Proteína Quinasa C-alfa/genética , ARNt Metiltransferasas/biosíntesis , Apoptosis/genética , Biomarcadores de Tumor/genética , Carcinogénesis/genética , Línea Celular Tumoral , Proliferación Celular/genética , Regulación Neoplásica de la Expresión Génica , Glioblastoma/patología , Humanos , Metionina/genética , Proteína Quinasa C-alfa/biosíntesis , ARN de Transferencia/genética , ARNt Metiltransferasas/genética
3.
Ann Chir ; 130(4): 261-3, 2005 Apr.
Artículo en Francés | MEDLINE | ID: mdl-15847864

RESUMEN

Leakage of oesophagojejunostomy is a severe complication of total gastrectomy. We present a technique allowing preoperative preservation of a defective oesophagojejunostomy: this technique involves closure of the cervical esophagus with stapler, double-lumen transanastomotic tube, mediastinal drainage and feeding jejunostomy.


Asunto(s)
Esofagostomía/métodos , Gastrectomía/efectos adversos , Yeyunostomía/métodos , Complicaciones Posoperatorias/cirugía , Adenocarcinoma/cirugía , Anciano , Anastomosis Quirúrgica , Femenino , Humanos , Reoperación , Neoplasias Gástricas/cirugía , Suturas
4.
Eur J Surg Oncol ; 30(8): 900-4, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15336738

RESUMEN

Pelvic malignancies frequently require post-operative radiation therapy that may induce small bowel damage at an incidence of 5-25%. Various surgical techniques have been reported to prevent acute and chronic radiation enteritis. This article describes the technical aspects of pelvic exclusion by an intrapelvic silicone breast prosthesis.


Asunto(s)
Enteritis/prevención & control , Intestino Delgado/efectos de la radiación , Neoplasias Pélvicas/radioterapia , Prótesis e Implantes , Traumatismos por Radiación/prevención & control , Elastómeros de Silicona , Implantes de Mama , Relación Dosis-Respuesta en la Radiación , Enteritis/etiología , Femenino , Estudios de Seguimiento , Humanos , Intestino Delgado/patología , Imagen por Resonancia Magnética , Neoplasias Pélvicas/patología , Neoplasias Pélvicas/cirugía , Dosificación Radioterapéutica , Medición de Riesgo , Sensibilidad y Especificidad , Resultado del Tratamiento
7.
N Engl J Med ; 337(3): 161-7, 1997 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-9219702

RESUMEN

BACKGROUND: We conducted a multicenter, randomized trial to compare preoperative chemoradiotherapy followed by surgery with surgery alone in patients with stage I and II squamous-cell cancer of the esophagus. METHODS: The preoperative combined therapy consisted of two one-week courses; each involved radiotherapy, in a dose of 18.5 Gy delivered in five fractions of 3.7 Gy each, and 80 mg of cisplatin per square meter of body-surface area, administered 0 to 2 days before the first day of radiotherapy. The surgical plan included one-stage en bloc esophagectomy and proximal gastrectomy by the abdominal and right thoracic routes, to be performed immediately after randomization in the group assigned to surgery alone and two to four weeks after the completion of preoperative chemoradiotherapy in the group assigned to combined therapy. RESULTS: A total of 297 patients entered the study; 11 were found to be ineligible, and 4 were lost to follow-up. Of the remaining 282, 139 were assigned to surgery alone and 143 to combined therapy. After a median follow-up of 55.2 months, no significant difference in overall survival was observed; the median survival was 18.6 months for both groups. As compared with the group treated with surgery alone, the group treated preoperatively had longer disease-free survival (P=0.003), a longer interval free of local disease (P=0.01), a lower rate of cancer-related deaths (P=0.002), and a higher frequency of curative resection (P=0.017). However, there were more postoperative deaths (P=0.012) in the group treated preoperatively with chemoradiotherapy. Three prognostic factors were found to influence survival in a multivariate analysis: the disease stage, based on computed tomography; the location of the tumor; and whether the surgical resection was curative. CONCLUSIONS: In patients with squamous-cell esophageal cancer, preoperative chemoradiotherapy did not improve overall survival, but it did prolong disease-free survival and survival free of local disease.


Asunto(s)
Antineoplásicos/uso terapéutico , Cisplatino/uso terapéutico , Neoplasias Esofágicas/tratamiento farmacológico , Neoplasias Esofágicas/cirugía , Neoplasias de Células Escamosas/tratamiento farmacológico , Neoplasias de Células Escamosas/cirugía , Antineoplásicos/efectos adversos , Cisplatino/efectos adversos , Terapia Combinada , Supervivencia sin Enfermedad , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/radioterapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Neoplasias de Células Escamosas/mortalidad , Neoplasias de Células Escamosas/radioterapia , Pronóstico , Análisis de Supervivencia
12.
J Chir (Paris) ; 132(12): 503-5, 1995 Dec.
Artículo en Francés | MEDLINE | ID: mdl-8815063

RESUMEN

Cystic dystrophy of the aberrant pancreas is a rare poorly understood condition which is difficult to diagnose and treat. The primary clinical signs are epigastralgia associated with poor general health and complications due to stenosis of the duodenum. Endoscopy gives the most information on tissue lesions and cystic formations in the duodenal mucosa. Although the condition is benign, and due to the lack of sufficient history in endoscopically treated cases, cystic dystrophy of the aberrant duodenal pancreas appears to require duodenopancreatectomy.


Asunto(s)
Páncreas/anomalías , Quiste Pancreático/cirugía , Adulto , Femenino , Humanos , Páncreas/cirugía , Pancreaticoduodenectomía
13.
Presse Med ; 24(9): 441-4, 1995 Mar 04.
Artículo en Francés | MEDLINE | ID: mdl-7746817

RESUMEN

In idiopathic thrombocytopenic purpura, intravenous immunoglobulin therapy is currently a treatment of choice. It is usually effective with little side-effects. Acute renal failure has been recently identified as a potential, though rare, complication of intravenous immunoglobulins. However, the mechanism remains unclear. A 53 year-old-woman with idiopathic thrombocytopenic purpura developed oliguric renal failure after high doses of intravenous immunoglobulins. Her renal function returned to normal after dialysis and plasmapheresis. This rapid normalization suggested that acute renal failure was functional. Since laboratory tests showed an increase in protidemia concomitant to the immunoglobulin therapy, acute renal failure was likely to be related to hyperosmolar renal damage.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Inmunoglobulinas Intravenosas/efectos adversos , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Lesión Renal Aguda/terapia , Femenino , Hemodinámica , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunoglobulinas Intravenosas/uso terapéutico , Pruebas de Función Renal , Persona de Mediana Edad , Plasmaféresis/métodos , Diálisis Renal/métodos
14.
Nephron ; 69(3): 259-66, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7753259

RESUMEN

Improvement in erythropoiesis following renal transplantation (RT) was assessed in 74 consecutive patients by serial measurements of serum erythropoietin (EPO), hematocrit, absolute reticulocyte count (ARC) and serum creatinine during the first month after RT. The reticulocyte maturity index (RMI) which provides an objective measure of red-cell maturity was assessed in 31 patients by flow cytometry using thiazole orange. In group I (n = 39) with immediate graft function, EPO levels increased rapidly from day 2 and remained elevated at the plateau between two and three times the upper limit of normal during the first 2 months. In group II (n = 29) with delayed graft function, EPO levels increased gradually from day 10 when renal function improved significantly. No particular significant biphasic pattern of secretion was detected in group I or II. In both groups, hematocrit rose to over 35% approximately 3 months after RT. In a third group (n = 6) with immediate postoperative acute blood loss and severe anemia, a hematocrit fall was followed by a steep increase in EPO levels with a negative correlation between hematocrit and EPO levels during the first 4 days. During acute rejection, EPO diminished significantly by more than 50% either on the day of diagnosis or on the following days in 8 patients. RMI increased by 25% over the pretransplantation values by 7 days on average before the ARC rose. Thus the RMI seems to be an early sensitive predictor of erythropoiesis after RT. EPO response after RT depends on graft function, and the early transient increase in EPO observed in patients with acute blood loss may explain the apparent biphasic response previously reported.


Asunto(s)
Eritropoyetina/sangre , Trasplante de Riñón , Reticulocitos/citología , Adolescente , Adulto , Anciano , Benzotiazoles , Creatinina/sangre , Eritrocitos/citología , Femenino , Citometría de Flujo , Rechazo de Injerto/sangre , Hematócrito , Humanos , Riñón/fisiología , Trasplante de Riñón/efectos adversos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Quinolinas , Recuento de Reticulocitos , Tiazoles
15.
J Chir (Paris) ; 131(11): 466-72, 1994 Nov.
Artículo en Francés | MEDLINE | ID: mdl-7860683

RESUMEN

The aim of this retrospective study on 184 operated cases was to propose a therapeutic management scheme for villous tumours of the rectum. Among the 184 operated patients, 167 (90,7%), mean age 65 years, were seen after a follow-up of 2 to 20 years. The tumour was most often localized in the rectal ampoula (141 cases) and was benign in 65 p. 100. Endoanal surgery was performed in 76 patients among whom recurrence was observed in 29.7%. Posterior exeresis (Kraske method) was performed in 52 cases with a recurrence rate of 31.9%). Finally, abdominoperineal amputation was performed 20 times, essentially for advanced stage tumours. Based on the statistical analysis of the recurrence factors for these different techniques, we have concluded that endoanal surgery predominates for benign tumours smaller than 5 cm situated at least 8 cm from the anus. Above the size of 5 cm, due to the major risk of tumourectomy, we believe rectal exeresis is the most rational treatment.


Asunto(s)
Adenoma Velloso/cirugía , Neoplasias del Recto/cirugía , Adenoma Velloso/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Neoplasias del Recto/mortalidad , Estudios Retrospectivos
17.
Soins ; (583): 4-8, 1994 Apr.
Artículo en Francés | MEDLINE | ID: mdl-8029717
18.
Soins ; (583): 9-14, 1994 Apr.
Artículo en Francés | MEDLINE | ID: mdl-8029723
19.
Artículo en Francés | MEDLINE | ID: mdl-7706656

RESUMEN

Peritoneal leiomyomatosis disseminata is an exceptional benign disease with characteristic multifocal subperitoneal smooth muscle cell growth. We report and exceptional case associating pelvic endometriosis and mimicking cancer of the ovary. Surgery was performed and was found a posteriori to be excessive in light of the good prognosis of this disease. Positive hormone receptor assays on the surgical specimen favoured ovarian steroid hormone involvement in the aetiopathology of this strange disease.


Asunto(s)
Leiomiomatosis/patología , Enfermedades Peritoneales/patología , Diagnóstico Diferencial , Endometriosis/patología , Femenino , Humanos , Leiomiomatosis/complicaciones , Leiomiomatosis/cirugía , Persona de Mediana Edad , Neoplasias Ováricas/patología , Enfermedades Peritoneales/complicaciones , Enfermedades Peritoneales/cirugía , Neoplasias Peritoneales/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...